Angiotensin-(1-7) in Treating Patients With Metastatic or Unresectable Solid Tumors

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed advanced solid tumor meeting 1 of the following criteria: * Metastatic disease * Unresectable disease * Standard curative or palliative measures do not exist or are no longer effective * Measurable or nonmeasurable disease * Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan * Nonmeasurable disease, defined as all other lesions, including small lesions (i.e., ≥ 1 unidimensionally measurable lesion \< 20 mm by conventional techniques or \< 10 mm by spiral CT scan) and truly nonmeasurable lesions, including any of the following: * Bone lesions * Ascites * Pleural or pericardial effusion * Lymphangitis cutis or pulmonis * Abdominal masses not confirmed and followed by imaging techniques * Cystic lesions * No lung cancer with recent hemoptysis * No brain metastasis PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Life expectancy \> 4 weeks * No evidence of bleeding diathesis * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Granulocyte count ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Creatinine clearance \> 30 mL/min * Bilirubin \< 2 mg/dL * AST and ALT \< 3 times upper limit of normal * No concurrent uncontrolled illness including, but not limited to, any of the following: * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Uncontrolled hypertension or hypotension * No psychiatric illness or social situation that would preclude informed consent or study compliance PRIOR CONCURRENT THERAPY: * At least 4 weeks since prior major surgery * At least 4 weeks since prior radiotherapy or chemotherapy (6 weeks for melphalan, nitrosoureas, or mitomycin C) * No concurrent therapeutic anticoagulation * No other concurrent investigational agents * No concurrent angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers * No concurrent combination antiretroviral therapy for HIV-positive patients